Arcus Biosciences Inc - Asset Resilience Ratio
Arcus Biosciences Inc (RCUS) has an Asset Resilience Ratio of 60.88% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Arcus Biosciences Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Arcus Biosciences Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Arcus Biosciences Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Arcus Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RCUS company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $593.00 Million | 60.88% |
| Total Liquid Assets | $593.00 Million | 60.88% |
Asset Resilience Insights
- Very High Liquidity: Arcus Biosciences Inc maintains exceptional liquid asset reserves at 60.88% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcus Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Arcus Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Arcus Biosciences Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Arcus Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 72.00% | $828.00 Million | $1.15 Billion | +14.28pp |
| 2023-12-31 | 57.72% | $632.00 Million | $1.09 Billion | -1.99pp |
| 2022-12-31 | 59.70% | $803.00 Million | $1.34 Billion | +37.63pp |
| 2021-12-31 | 22.07% | $351.39 Million | $1.59 Billion | -49.82pp |
| 2020-12-31 | 71.89% | $555.23 Million | $772.29 Million | +7.73pp |
| 2019-12-31 | 64.17% | $130.33 Million | $203.11 Million | -3.30pp |
| 2018-12-31 | 67.47% | $185.48 Million | $274.93 Million | +26.90pp |
| 2017-12-31 | 40.57% | $77.28 Million | $190.49 Million | +9.82pp |
| 2016-12-31 | 30.75% | $33.74 Million | $109.70 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develop… Read more